News
-
Orion Receives Positive Phase II Study Results Of A New Levodopa Product For Parkinson's Disease
10/24/2012
ODM-101, a new levodopa product currently developed by Orion for the treatment of Parkinson's disease, has successfully completed Phase II Proof of Concept trial. The key results indicate that ODM-101 was more efficacious than the reference product Stalevo® in the treatment of advanced Parkinson's disease patients. The study included more than 100 patients in Europe.
-
Bayer's Investigational Riociguat Meets Primary Endpoint In Phase III Study Of Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
10/23/2012
Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.
-
Phase IIa Laquinimod Trial Results Show Positive Data For Potential Use In Active Crohn's Disease
10/22/2012
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn's disease (CD).
-
Hybrigenics Starts Phase II Clinical Trial Of Inecalcitol In Chronic Lymphocytic Leukemia
9/11/2012
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, recently announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL).
-
The ‘NEU²’ Consortium Receives A Further Euro 20M Boost From The German Government To Expand Its Project Portfolio And Move Forward Its Public-Private Fund Focused On Therapies For Multiple Sclerosis And Related Neurological Diseases
8/29/2012
In the latest round of the “BioPharma” competition funded by the German Federal Ministry of Education and Research (BMBF), the NEU² consortium has been granted a further Eur 20 M.
-
Eaton Scientific Announces Clinical Trial Plans For Tropine 3 - Company To Seek FDA Approval As Novel Prescription Drug For Non-Hormonal Treatment Of Hot Flashes In Menopausal Women
8/28/2012
Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce select details of its planned multi-phase multi-location clinic trials for FDA approval of its novel drug indication Tropine 3, containing currently FDA approved Homatropine, in oral an suspension.
-
Autism And Cord Blood Stem Cells: FDA Gives Green Light For Groundbreaking Clinical Trial
8/21/2012
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism.
-
Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis
8/8/2012
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
FDA Gives Miami Project To Cure Paralysis Green Light To Pursue Human Trial
7/31/2012
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.
-
Synteract To Host Joint Statistical Meeting Roundtable In San Diego
7/24/2012
Synteract, Inc., a full-service contract research organization (CRO), will host the roundtable, “Beyond number-crunching and data-monitoring: challenging roles for CRO statisticians,” at the Joint Statistical Meetings (JSM), on August 1, 2012 at 12:30 p.m., PDT. The roundtable will be moderated by Jia Hu, biostatistician II, from Synteract. JSM is the largest gathering of statisticians held in North America, attended by more than 6,000 people.